Navigation Links
Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
Date:10/3/2007

efined by RECIST criteria), decreases in CA 19-9 (a tumor marker in some patients with pancreatic cancer), and the overall duration of response in those patients achieving a response. In addition, amelioration of pain and reduction in analgesic use will be quantified as another measure of clinical benefit.

Patients will remain on study until tumor progression or death, unacceptable toxicity, withdrawal of consent or discontinuation based upon investigator discretion. Patients will be followed for survival for up to one year after enrollment in the study.

"We are structuring a diversified Phase 2 program for TPI 287 that will allow us to effectively evaluate this unique taxane as a treatment option for patients who have failed other therapeutic regimens," commented Dr. Sandra Silberman, chief medical officer of Tapestry Pharmaceuticals. "Our primary goal in this study is to rigorously explore the activity of TPI 287 in patients with advanced pancreatic cancer who have failed first line therapy. We are also interested in building more experience with this compound in the clinic, defining its safety and side-effect profile and tracking its impact on the quality of patients' lives, particularly as it relates to pain and pain management."

Clinical Program for TPI 287

In addition to the dosing of the first patient in this Phase 2 advanced pancreatic cancer trial and the on-going Phase 2 clinical trial in patients with advanced, hormone refractory prostate cancer, the Company may begin a third Phase 2 clinical trial in patients with glioblastoma multiforme, a primary cancer of the central nervous system. In all of these Phase 2 studies, TPI 287 will be administered as an intravenous dosage form.

In parallel to these Phase 2 studies, the company plans to initiate a Phase 1b study evaluating the oral bioavailability of TPI 287. In 2008, assuming feasibility of oral dosing from this study, the company may initiate a Phase 1b/2 study of the combin
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... WOODCLIFF LAKE, N.J. and SAN ... announced today that its parent company Eisai Co., Ltd. ... Haruo Naito , "Eisai") and Halozyme Therapeutics, Inc. ... and CEO: Dr. Helen Torley , "NASDAQ: HALO") ... eribulin mesylate (brand name: Halaven ® , "eribulin") in ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... N.J., Dec. 8, 2011  At the Radiological Society ... announced its plans to enter the radiology display ... in display technology to bring a comprehensive line ... "Sony has set the standard for ...
... Dec. 8, 2011 Ecology Coatings, Inc. ... development of nanotechnology-enabled, ultraviolet-curable advanced coatings, today announced ... the rigorous requirements of the healthcare industry.  The ... patient wristband and is benzophenone free—a request that ...
Cached Medicine Technology:Ecology Coatings Develops UV-Curable Coatings for Medical Wristbands 2Ecology Coatings Develops UV-Curable Coatings for Medical Wristbands 3
(Date:7/31/2015)... Orlando, FL (PRWEB) , ... July 31, 2015 , ... ... visiting the United States for temporary work, study or family visit for the past ... in their 80s and 90s are able to travel and spend time with their ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... apnea (OSA) and the growing number of individuals who remain undiagnosed, treatment options ... continue to shy away from traditional CPAP therapy due to its overall lack ...
(Date:7/30/2015)... ... ... The Venetian on Grace Bay in the Turks & Caicos Islands is pleased to announce ... 40% on their stay while enjoying some of the most beautiful ocean views in the ... a chance to reconnect with loved ones and rediscover one's best self. The sea ...
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the country see the ... a serious challenge. Because of growing competition, it is more important than ever ... , The team at Wound Care Advantage has found that while ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The connection between a healthy head of hair ... The loss of a full head of hair can have a devastating impact on the ... is perceived in the work place, the consequences of hair loss are not to be ...
Breaking Medicine News(10 mins):Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Two ... people with the rare bone marrow disorder called myelofibrosis. ... brand name Jakafi, won,t cure myelofibrosis, it can help ease ... to the studies. "This is probably the most ...
... report published this week in the New England Journal ... melanoma patients with a specific genetic mutation benefit from the ... to 15.9 months. In patients who responded, the drug stopped ... patients with a BRAF V600 mutation, this drug is a ...
... of Traumatic Brain Injury Research at Kessler Foundation, is an ... on March 6, 2012, in Washington, DC. Dr. Grafman ... brain injury. A well known expert, he will focus on ... injury and genetic polymorphisms on social abilities and quality of ...
... Colin Farrelly wants to see more research into remarkable ... live 100 years disease-free. He describes the current pathology-based ... biology" and suggest more resources should be focused on ... the question ,what causes disease?, is the most significant ...
... -- Strict enforcement of underage drinking laws reduces the ... new study suggests. State lawmakers have relied heavily on ... of alcohol under the legal age laws -- to control ... on young people aged 15 to 24 from the FBI,s ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... FDA mandate that would have forced tobacco companies to ... The proposed requirement from the U.S. Food and Drug ... would have emblazoned cigarette packaging with images of people ...
Cached Medicine News:Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Kessler Foundation neuroscientist addresses 2nd Annual TBI Conference in Washington DC 2Health News:Strict Underage Drinking Laws May Deter Delinquency in Teens 2Health News:Judge Blocks Plan for Graphic Cigarette Warnings 2
... basic laboratory system for pH and temperature ... obtained when used with a temperature probe ... and easy one and two-point calibration with ... (pH 1.68, 4.00, 7.00, 10.01 and 12.45) ...
... Detectors provide unmatched value and flexibility ... automation needs. Capable of performing fluorescence, ... same instrument, the DTX Series can ... be integrated seamlessly with Beckman Coulters ...
... Designed for High Throughput Screening ... of assays into HTS by sharing ... performance of Analyst AD, fluorescence intensity, ... Optimized for seamless integration into ...
... features for assay development and basic ... Reduces the inevitable transfer time required ... developed to meet the challenges of ... unparalleled detection performance for Fluorescence Intensity, ...
Medicine Products: